These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 9588545)

  • 21. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel use of endogenous GH-measurement directly after transsphenoidal microsurgery in acromegaly treated with pegvisomant.
    Lüdecke DK; Crock PA; Bidlingmaier M; Schuppert F
    Exp Clin Endocrinol Diabetes; 2013 Aug; 121(8):509-12. PubMed ID: 23765756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations.
    Ludecke DK; Abe T
    Neuroendocrinology; 2006; 83(3-4):230-9. PubMed ID: 17047388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of continuous long-term intravenous application of octreotide via an implantable pump system in acromegaly resistant to operative and X-ray therapy.
    Hildebrandt G; Zierski J; Csecsei G; Mueller HW; Stracke H
    Acta Neurochir (Wien); 1992; 117(3-4):160-5. PubMed ID: 1414517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
    Hofstetter CP; Mannaa RH; Mubita L; Anand VK; Kennedy JW; Dehdashti AR; Schwartz TH
    Neurosurg Focus; 2010 Oct; 29(4):E6. PubMed ID: 20887131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery.
    Yan JL; Chang CN; Chuang CC; Hsu PW; Lin JD; Wei KC; Lee ST; Tseng JK; Pai PC; Chen YL
    J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of surgical outcome and early criteria of remission in acromegaly.
    Antunes X; Ventura N; Camilo GB; Wildemberg LE; Guasti A; Pereira PJM; Camacho AHS; Chimelli L; Niemeyer P; Gadelha MR; Kasuki L
    Endocrine; 2018 Jun; 60(3):415-422. PubMed ID: 29626274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acromegaly: a review of current medical therapy and new drugs on the horizon.
    Fleseriu M; Delashaw JB; Cook DM
    Neurosurg Focus; 2010 Oct; 29(4):E15. PubMed ID: 20887125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of pituitary adenomas].
    Mezosi E; Nemes O
    Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Outcome of surgical treatment for acromegaly performed by a single neurosurgeon and cumulative meta-analysis].
    Boeving A; Borba LA; Rodrigues AM; Orichowski EB; Paz Filho GJ; Santos CM; Boguszewski CL
    Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):884-92. PubMed ID: 17160212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
    Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
    J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2476-82. PubMed ID: 10902796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy in acromegaly].
    Góth M; Korbonits M
    Orv Hetil; 2004 Apr; 145(16):867-71. PubMed ID: 15156692
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.
    Jane JA; Starke RM; Elzoghby MA; Reames DL; Payne SC; Thorner MO; Marshall JC; Laws ER; Vance ML
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2732-40. PubMed ID: 21715544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.
    De P; Rees DA; Davies N; John R; Neal J; Mills RG; Vafidis J; Davies JS; Scanlon MF
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3567-72. PubMed ID: 12915637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
    Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.